On September 13th, journalist Vivienne Parry interviewed InMed Pharmaceuticals’ President and CEO, Eric A. Adams, and BayMedica’s co-founder, Shane Johnson. In their first interview together, Eric and Shane talked about the acquisition and their shared vision of the combined company.
![](https://www.inmedpharma.com/wp-content/uploads/2024/07/InMed_INM-089-Article-Investor-Wire-768x398.png)
Article: InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-089, a Promising Treatment for Age-Related Macular Degeneration
In this article, read about the prevalence of age-related macular degeneration and InMed’s promising preclinical studies of INM-089, a small molecule drug candidate in development